Skip to main content
Equibles
XAGE logo

XAGE · Longevity Health Holdings, Inc. · Metrics

Track XAGE — free

Use XAGE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XAGE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.92 -0.40 (-17.41%) At close · Sep 12
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$685,663
Shares
2.48M
Volume · Sep 12 107.4K Avg daily vol (3M) 1.79M

XAGE metrics

53 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.92
Market cap
$685,663

Price action

20 metrics
Price change (1W)
-21.2%
Price change (30D)
—
Price change (3M)
-26.3%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
247.1%
Annualized volatility (3M)
262.0%
Beta
—
RSI (14D)
34.7
Price vs SMA 50
-35.0%
Price vs SMA 200
—
Avg volume (3M)
1.79M
Relative volume
0.1
Average dollar volume
$9.89M

Company

3 metrics
Sector
Consumer Defensive
Industry
Household & Personal Products
Shares outstanding
2.48M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 246.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-995.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
59.0%
Operating margin
-343.6%
Trailing 12 months
Net margin
-404.8%
Gross profit (TTM)
$994,840
Operating profit (TTM)
−$5.79M
Net income (TTM)
−$6.83M
Trailing 12 months
Diluted EPS (TTM)
$-4.06
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.14
Gross profit per diluted share (TTM)
$0.67
Operating profit per diluted share (TTM)
$-4.36
EBITDA per diluted share (TTM)
$-4.32
Net income per diluted share (TTM)
$-4.31
Operating cash flow per diluted share (TTM)
$-1.95
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.43
Stock compensation per diluted share (TTM)
$0.46
Book value per share
$-3.29

Growth

11 metrics
Revenue growth YoY
-21.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.69M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+91.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-647.0%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
−$5.73M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$35,471
Total assets
$1.06M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.45M
Capital expenditures (TTM)
—
R&D (TTM)
$492,209
SG&A (TTM)
—
Stock compensation (TTM)
$608,324
R&D / revenue
29.2%
Stock compensation / revenue
36.1%

Ownership (13F)

9 metrics
13F filers
3
13F filer change QoQ
0
Institutional ownership
0.9%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+0.0%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1842939 CUSIP 142922129 Visit website Investor relations